Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyper-FHX Chemoradiotherapy for Intermediate Stage Head and Neck Cancer
NCT00002951Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Jun 1996
- Primary completion
- Jun 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil and hydroxyurea in head and neck cancer (HNC), sponsored by University of Chicago. Primary endpoint: Locoregional control rate at 8 years. Started Jun 1996; status: completed.
02
Drugs
fluorouracilhydroxyurea
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT00002951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002951.